PRA Health Sciences Named Clinical Research Company of the Year

Raleigh, North Carolina, UNITED STATES

RALEIGH, N.C., April 18, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc., (PRA) (NASDAQ:PRAH) is pleased to announce it was once again recognized as the Best Clinical Research Company of the Year. PRA received the award at the PharmaTimes Clinical Researcher of the Year Americas ceremony in Atlanta, Georgia. This is the second year in a row that PRA has received this prestigious recognition. In 2015 PRA was also named the Best International Clinical Company of the Year.

A photo accompanying this announcement is available at

“This is an incredible honor for us,” said Michael Brooks, Executive Vice President, Product Registration, Americas. “PRA employees are passionate about their clinical development work and this award is recognition of their talent and dedication.”

PRA was well represented in the competition with 16 finalists in five different categories. Individual gold award recipients include:

  • Experienced CRA: Raquel Amorim
  • Strategic Partnership Team (PRA and CytRx): Stephanie Gonzalez, Sinead Pitts, Miriam Price

Organized by PharmaTimes, the Clinical Researcher of the Year competition is considered a key barometer of quality standards in the Clinical Research Organization (CRO) industry. The multi-stage competition is organized by an independent executive steering committee drawn from senior industry leaders from big and small pharma, leading CROs, and professional membership associations.


PRA is one of the world's leading global contract research organizations, by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes approximately 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East, and approximately 12,000 employees worldwide. Since 2000, PRA has performed approximately 3,300 clinical trials worldwide and has worked on more than 100 marketed drugs across several therapeutic areas. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 60 drugs. To learn more about PRA, please visit

CRoY Photo_PharmaTimes_2016.jpg

Contact Data